This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Aug;80(2):171-173.

doi: 10.1016/j.eururo.2021.04.031. Epub 2021 May 7.

Systemic Therapy for Advanced Non-clear-Cell Renal Cell Carcinoma: Slow but Definite Progress

Daniel M Geynisman¹, Elizabeth R Plimack²

Affiliations

Affiliations

¹ Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
² Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA. Electronic address: elizabeth.plimack@fccc.edu.

PMID: 33972094
DOI: 10.1016/j.eururo.2021.04.031

Editorial

Systemic Therapy for Advanced Non-clear-Cell Renal Cell Carcinoma: Slow but Definite Progress

Daniel M Geynisman et al. Eur Urol. 2021 Aug.

. 2021 Aug;80(2):171-173.

doi: 10.1016/j.eururo.2021.04.031. Epub 2021 May 7.

Authors

Daniel M Geynisman¹, Elizabeth R Plimack²

Affiliations

¹ Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
² Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA. Electronic address: elizabeth.plimack@fccc.edu.

PMID: 33972094
DOI: 10.1016/j.eururo.2021.04.031

No abstract available

PubMed Disclaimer

Comment on

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK, Fishman MN. Hutson TE, et al. Eur Urol. 2021 Aug;80(2):162-170. doi: 10.1016/j.eururo.2021.03.015. Epub 2021 Apr 16. Eur Urol. 2021. PMID: 33867192 Clinical Trial.

Similar articles

An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC).
D'Angelo A, Bagby S, Di Pierro G, Chirra M, Nobili S, Mini E, Villari D, Roviello G. D'Angelo A, et al. Crit Rev Oncol Hematol. 2020 May;149:102921. doi: 10.1016/j.critrevonc.2020.102921. Epub 2020 Mar 3. Crit Rev Oncol Hematol. 2020. PMID: 32172222 Review.
Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
Ito K. Ito K. Int J Urol. 2019 Sep;26(9):868-877. doi: 10.1111/iju.14027. Epub 2019 Jun 10. Int J Urol. 2019. PMID: 31183903 Review.
Re: Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma.
Greco F, Mirone V. Greco F, et al. Eur Urol. 2015 Aug;68(2):336. doi: 10.1016/j.eururo.2015.03.012. Eur Urol. 2015. PMID: 26149726 No abstract available.
Temsirolimus for advanced renal cell carcinoma.
Figlin RA. Figlin RA. Clin Adv Hematol Oncol. 2007 Nov;5(11):893. Clin Adv Hematol Oncol. 2007. PMID: 18185488 No abstract available.
Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
Parikh M, Lara PN Jr. Parikh M, et al. Annu Rev Med. 2018 Jan 29;69:209-221. doi: 10.1146/annurev-med-041916-124132. Epub 2017 Nov 16. Annu Rev Med. 2018. PMID: 29144835 Review.

See all similar articles

Cited by

Activation of RHO-GTPase gene pattern correlates with adverse clinical outcome and immune microenvironment in clear cell renal cell carcinoma.
Guo K, Ma P, Yang Q, Xu L, Zhang B, Zhang H, Zheng Z, Zhuo Z. Guo K, et al. Clin Exp Med. 2025 Feb 25;25(1):67. doi: 10.1007/s10238-025-01593-3. Clin Exp Med. 2025. PMID: 39998699 Free PMC article.
TIMP1 shapes an immunosuppressive microenvironment by regulating anoikis to promote the progression of clear cell renal cell carcinoma.
Li Q, Wei K, Zhang X, Lv Y, Li M, Zhou C, Su S, Hou D, Hou J. Li Q, et al. Aging (Albany NY). 2023 Sep 8;15(17):8908-8929. doi: 10.18632/aging.205005. Epub 2023 Sep 8. Aging (Albany NY). 2023. PMID: 37688768 Free PMC article.
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
Adashek JJ, Breunig JJ, Posadas E, Bhowmick NA, Ellis L, Freedland SJ, Kim H, Figlin R, Gong J. Adashek JJ, et al. Drugs. 2022 Mar;82(4):439-453. doi: 10.1007/s40265-022-01683-6. Epub 2022 Feb 17. Drugs. 2022. PMID: 35175588 Review.
Surgical Outcomes and Genomic Insights of Nonclear Cell Renal Cell Carcinoma With Synchronous and Metachronous Nodal Disease.
Eismann L, Zucker M, Dawidek MT, Reese SW, Calderon LP, Aulitzky A, Stief CG, Coleman JA, Kotecha RR, Carlo M, Chen Y, Reznik E, Russo P, Hakimi AA. Eismann L, et al. Urol Pract. 2024 Sep;11(5):860-870. doi: 10.1097/UPJ.0000000000000623. Epub 2024 Jun 12. Urol Pract. 2024. PMID: 38913557

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information